Home » NOVARTIS SEEKS EU APPROVAL FOR GLIVEC APPLICATION
NOVARTIS SEEKS EU APPROVAL FOR GLIVEC APPLICATION
Swiss-based drug firm Novartis (NOVN.VX: Quote, Profile, Research) is seeking European approval to market its leukaemia treatment Glivec, the company said on Tuesday. Novartis hopes to market Glivec, or Gleevec, as a treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, either alone or in combination with chemotherapy.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May